Nuwellis, Inc. (NUWE) stock
NUWENasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 10/3082% below fair value
$4.90−0.13 (-2.58%)
Close on Nov 13, 2026Market cap $2.65MP/E –Yield –
Nuwellis r&d expenses
Research and development expenses are spending on new products and technology.
Nuwellis's R&D Expenses for the twelve months ending Sep 30, 2026 was $4.14M, up 55.6% year over year. For fiscal 2025 it was $2.71M, down 15.5% from the year before. Over ten years it grew -17.1% a year on average. The highest annual figure on record is $17.67M in fiscal 2015.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.71M | -15.5% |
| FY2024 | Dec 31, 2024 | $3.21M | -40.8% |
| FY2023 | Dec 31, 2023 | $5.42M | +24.9% |
| FY2022 | Dec 31, 2022 | $4.34M | -12.8% |
| FY2021 | Dec 31, 2021 | $4.98M | +35.7% |
| FY2020 | Dec 31, 2020 | $3.67M | -21.5% |
| FY2019 | Dec 31, 2019 | $4.67M | +53.0% |
| FY2018 | Dec 31, 2018 | $3.05M | +106.1% |
| FY2017 | Dec 31, 2017 | $1.48M | -81.7% |
| FY2016 | Dec 31, 2016 | $8.11M | -54.1% |
| FY2015 | Dec 31, 2015 | $17.67M | +4.7% |
| FY2014 | Dec 31, 2014 | $16.87M | +25.0% |
| FY2013 | Dec 31, 2013 | $13.50M | +68.7% |
| FY2012 | Dec 31, 2012 | $8.00M | -28.5% |
| FY2011 | Dec 31, 2011 | $11.20M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $584.00K | -3.2% |
| Q2 FY2026 | Jun 30, 2026 | $942.00K | +39.6% |
| Q1 FY2026 | Mar 31, 2026 | $1.73M | +214.2% |
| Q4 FY2025 | Dec 31, 2025 | $884.00K | +6.4% |
| Q3 FY2025 | Sep 30, 2025 | $603.00K | +24.1% |
| Q2 FY2025 | Jun 30, 2025 | $675.00K | +21.0% |
| Q1 FY2025 | Mar 31, 2025 | $550.00K | -58.8% |
| Q4 FY2024 | Dec 31, 2024 | $831.00K | -39.4% |
| Q3 FY2024 | Sep 30, 2024 | $486.00K | -56.5% |
| Q2 FY2024 | Jun 30, 2024 | $558.00K | -62.9% |
| Q1 FY2024 | Mar 31, 2024 | $1.33M | -6.6% |
| Q4 FY2023 | Dec 31, 2023 | $1.37M | +14.2% |
| Q3 FY2023 | Sep 30, 2023 | $1.12M | +20.4% |
| Q2 FY2023 | Jun 30, 2023 | $1.51M | +36.0% |
| Q1 FY2023 | Mar 31, 2023 | $1.43M | +29.1% |
| Q4 FY2022 | Dec 31, 2022 | $1.20M | +6.2% |
| Q3 FY2022 | Sep 30, 2022 | $928.00K | -46.2% |
| Q2 FY2022 | Jun 30, 2022 | $1.11M | -5.7% |
| Q1 FY2022 | Mar 31, 2022 | $1.11M | +16.8% |
| Q4 FY2021 | Dec 31, 2021 | $1.13M | +7.9% |
| Q3 FY2021 | Sep 30, 2021 | $1.73M | +98.2% |
| Q2 FY2021 | Jun 30, 2021 | $1.17M | +32.7% |
| Q1 FY2021 | Mar 31, 2021 | $947.00K | +9.6% |
| Q4 FY2020 | Dec 31, 2020 | $1.05M | +10.0% |
| Q3 FY2020 | Sep 30, 2020 | $871.00K | -21.7% |
| Q2 FY2020 | Jun 30, 2020 | $885.00K | -31.8% |
| Q1 FY2020 | Mar 31, 2020 | $864.00K | -34.0% |
| Q4 FY2019 | Dec 31, 2019 | $953.00K | +0.7% |
| Q3 FY2019 | Sep 30, 2019 | $1.11M | +12.9% |
| Q2 FY2019 | Jun 30, 2019 | $1.30M | +101.7% |
| Q1 FY2019 | Mar 31, 2019 | $1.31M | +173.5% |
| Q4 FY2018 | Dec 31, 2018 | $946.00K | +97.5% |
| Q3 FY2018 | Sep 30, 2018 | $985.00K | +168.4% |
| Q2 FY2018 | Jun 30, 2018 | $643.00K | +96.6% |
| Q1 FY2018 | Mar 31, 2018 | $479.00K | +55.5% |
| Q4 FY2017 | Dec 31, 2017 | $479.00K | -19.9% |
| Q3 FY2017 | Sep 30, 2017 | $367.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $327.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $308.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $598.00K | – |
See a number that looks wrong?